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Abstract
Background: The universal presence of a gene (SMN2) nearly identical to the mutated SMN1 gene responsible for Spinal
Muscular Atrophy (SMA) has proved an enticing incentive to therapeutics development. Early disappointments from
putative SMN-enhancing agent clinical trials have increased interest in improving the assessment of SMN expression in
blood as an early ‘‘biomarker’’ of treatment effect.
Methods: A cross-sectional, single visit, multi-center design assessed SMN transcript and protein in 108 SMA and 22 age and
gender-matched healthy control subjects, while motor function was assessed by the Modified Hammersmith Functional
Motor Scale (MHFMS). Enrollment selectively targeted a broad range of SMA subjects that would permit maximum power to
distinguish the relative influence of SMN2 copy number, SMA type, present motor function, and age.
Results: SMN2 copy number and levels of full-length SMN2 transcripts correlated with SMA type, and like SMN protein
levels, were lower in SMA subjects compared to controls. No measure of SMN expression correlated strongly with MHFMS. A
key finding is that SMN2 copy number, levels of transcript and protein showed no correlation with each other.
Conclusion: This is a prospective study that uses the most advanced techniques of SMN transcript and protein
measurement in a large selectively-recruited cohort of individuals with SMA. There is a relationship between measures of
SMN expression in blood and SMA type, but not a strong correlation to motor function as measured by the MHFMS. Low
SMN transcript and protein levels in the SMA subjects relative to controls suggest that these measures of SMN in accessible
tissues may be amenable to an ‘‘early look’’ for target engagement in clinical trials of putative SMN-enhancing agents. Full
length SMN transcript abundance may provide insight into the molecular mechanism of phenotypic variation as a function
of SMN2 copy number.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
neuromuscular disorder that manifests across a wide range of
severity. The cardinal clinical feature of SMA – diffuse skeletal
muscle weakness – is a consequence of dysfunction or loss of alpha
motor neurons. SMA is caused by loss-of-function mutations or
deletions of the gene SMN1 (Gene ID=6606). A wide range of
disease severity can be partially attributed to the presence of
variable copy number of a neighboring near-identical gene, SMN2
(Gene ID=6607) [1–3]. A single base pair difference between
these two genes greatly reduces the efficiency of exon 7 inclusion
into mature transcripts from the SMN2 gene, but the coded
protein sequence from full length SMN2 derived transcripts is
unaffected by this change. SMN2 thus produces only a fraction of
the functional full length protein compared to SMN1 [4]. The
SMN gene is constitutively expressed in all eukaryotic cells and
necessary to cell viability [5–8]. Motor neurons are particularly
vulnerable to reduced SMN protein levels for reasons unknown.
The invariable presence of the partially functional disease-
ameliorating SMN2 gene in individuals with SMA offers an
attractive target for development of therapeutics [9]. Proof-of-
concept studies with small molecule, antisense oligonucleotide or
gene therapy approaches targeting various mechanisms to
upregulate expression of SMN2 have extended survival and
improved motor function in SMN-deficient animal models [10–
16]. Clinical trials of available putative SMA treatments that non-
specifically act on SMN expression have, so far, failed to
demonstrate efficacy [17–19].
One impediment to efficient trial design is that the typical
individual with SMA old enough to cooperate with motor function
testing declines very slowly [20]. Many affected children settle into
a plateau phase with stable function for years even though they
may have manifested progressive weakness in the first year or two
of life [21]. The consequence of this course is that a meaningful
attenuation of the rate of degeneration would necessarily take a
long time to demonstrate. Availability of a valid clinical measure of
SMN expression could thus accelerate clinical trials of an SMN-
enhancing therapeutic, particularly in the early, dose-finding,
phase of development. Given that most new treatments currently
under development intend to increase SMN synthesis in the
nervous system, measurement of the abundance of SMN transcript
or protein in tissues accessible to clinical sampling could be an
immediate and plausible biomarker that fulfills the need for an
early read-out of target engagement.
The continuous spectrum of SMA phenotype severity is
generally divided into three ‘‘Types’’ of SMA based upon the
history of specific gross motor abilities achieved before the disease
curtailed further developmental progress [22]. ‘‘Type I’’ defines
those who never sat independently, ‘‘Type II’’ those who sat but
never walked, and ‘‘Type III’’ those who were able to achieve
independent ambulation. Over time, an individual having a milder
type of SMA may decline to a level that overlaps in function with
that manifested at an early point in the course of individuals
affected by more severe types. The genomic number of SMN2
copies correlates with SMA types [1,2]. Severity of motor
impairment in SMA is likely multifactorial, although disabling
mutation of SMN is the essential first step. The potential broad
range of SMA phenotype that is predicted by loss of SMN1 is
focused to some extent by characterization of SMN2 copy
number, but within each specific SMN2 genotype there is broad
spectrum of motor function, and over time the severity of motor
impairment can vary even more.
The BforSMA study was designed to explore potential
biomarkers of disease severity in accessible peripheral tissues –
blood and urine – that may be of value in the execution of clinical
trials. The cohort was selectively recruited to represent subjects
with a wide range of SMA type, motor function, and age, who
were then characterized clinically in a manner that would best
power two independent projects. Results of the first project, an
unbiased biomarker discovery effort, are presented in a companion
paper (see companion paper, Finkel et al.[55]). Here, we present
the second project, a targeted analysis of relationships between
SMN transcript and protein levels to SMN genotype, SMA clinical
type, present motor function, and age. The project had two major
goals. The first was to determine whether a previously identified
association between SMN2 copy number and disease severity
could be confirmed in an SMA cohort prospectively recruited to
include individuals having all three types of SMA manifesting a
broad range of motor impairment. A second, more focused, goal
was to evaluate a possible relationship between SMN transcripts
and protein levels in blood samples from SMA subjects compared
to controls, and within the range of SMA clinical severity.
Relationships between any of these measures of SMN in blood
samples and clinical features may, with proper further develop-
ment, prove invaluable for clinical trials of SMN-enhancing
therapeutics.
Important to this project was the recognition that age is an
important potential confounder to be included in the statistical
analysis. The power of this is enhanced by targeted recruitment of
a clinical cohort in which SMA type and age are not highly
correlated. At the outset of the study, the extent to which this
broad distribution could be accomplished was unknown, given
early childhood mortality of subjects with SMA Type I. Site
investigators were encouraged to keep this goal in mind during
subject recruitment.
To date, studies of SMN transcript and protein levels from
amniocytes, skin fibroblasts, lymphocytes or peripheral blood
mononuclear cells (PBMCs) from SMA subjects have reported
variable results, but a general correlation of transcript or protein
quantity with phenotype is identified only in individuals at the
lower end of the SMA functional continuum [23–27]. Protein
levels in tissues from SMA Type I infants were noticeably lower
than those of healthy controls, while the differences in protein
levels between Types II, III, carriers and control subjects were not
significant. Existing studies have not controlled for present level of
motor function or subject age, and the possibility that these factors
undermine or enhance the relationship of blood assessments of
SMN to clinical variables is unexplored. In addition, newly
developed SMN transcript measurements by absolute quantifica-
tion and improved ELISA-based protein assays have the
advantage of increased sensitivity and reliability [24–26], and
may prove helpful in characterizing the relationships between
protein and disease severity in various tissues. It is thus not yet
clear if blood-derived SMN transcript or protein levels can be used
as a sensitive and meaningful marker of disease severity.
Materials and Methods
Planning and Objectives
The protocol was developed by a combination of SMA patient
advocates, experts in biostatistics and bioinformatics, basic
scientists investigating the biology of SMA, drug metabolism and
pathway experts, and clinical trial specialists. The protocol
supported two related, but independent, objectives: (1) an unbiased
protein, metabolite and transcript biomarker discovery analysis,
and (2) the SMN-targeted biomarker analysis reported here,
SMN Expression in SMA
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e33572
which intends to identify the relationship of quantative measures
of SMN expression to clinical  features  of  SMA.  A  leading
instrument for the measurement of gross motor function in SMA
is the Modified Hammersmith Functional Motor Scale (MHFMS),
and although this scale was initially designed and validated
only for those with Type II SMA, it  is  suitable also to evaluate
Type III individuals who have lost independent ambulation and
to a lesser extent to some of those with only weak ability to
walk [28]. It is not suitable for evaluation  of  many with  SMA
III. The MHFMS was used to assess all SMA
control subjects. Subjects with Type I SMA were assigned a 
Hammersmith value of zero.
Study Design
A cross-sectional, single visit, multi-center, exploratory study
design was employed. Blood for SMN transcript and protein
analysis and SMN2 copy number determination was collected. No
therapeutic intervention occurred. There was special emphasis on
enrolling children as subjects across a range phenotype severity.
The full protocol is available in the Appendix S1.
Study Management
The administration and data coordination of the trial was
conducted by the New England Research Institutes (NERI,
Watertown, MA). A protocol committee was established to design
the protocol and review potential violations as the trial progressed.
Eighteen academic clinical sites headed by investigators with
special expertise in the care of children with SMA participated in
the study. A meeting of investigators and clinical evaluators from
each study site was held to introduce them to the study protocol.
All data entry was performed via a secure internet-based website.
Sample collection, handling and chain of custody procedures were
designed to ensure the best quality specimens for biomarker
analysis. Samples were divided for specific analysis and shipped
from study sites to the central lab, PPD, Inc. (Highland Heights,
KT.) SMN transcripts were measured by Dr. F. Danilo Tiziano
laboratory (Istituto di Genetica Medica, Universita` Cattolica S.
Cuore, Roma, Italy), SMN2 copy number from blood were
analyzed by Expression Analysis, Inc. (Durham, NC), and SMN
protein analysis by an ELISA assay developed and run at Enzo
Life Sciences (Ann Arbor, MI). The Project Director and Data
Management group at NERI was responsible for data processing
while their Biostatistics group handled the data analyses.
Ethics Statement
Institutional review board (IRB) approval for the protocol was
obtained from each BforSMA clinical site before enrollment at
that site and from the central Institutional Review Board, New
England Research Institutes. Written informed consent for
participation was obtained from the legal guardians of all
subjects and assent for participation was obtained directly from
subjects whenever applicable. This trial was registered with
ClinicalTrials.gov with identifier NCT00756821.
Sample Size Determination and Enrollment
The number and type of subjects enrolled was based upon the
expected power necessary for the unbiased discovery project. The
sample size had an 80% power at level 0.05 to detect an effect size
of 0.6 standard deviations between SMA and controls, which is
considered a moderate difference. An unbalanced number of
subjects from the three types of SMA for targeted enrollment was
selected (15 Type I, 45 Type II, and 40 Type III SMA subjects) in
part due to the expectation that recruitment of eligible subjects
with SMA Type I across the full age range would be difficult due
to the high level of mortality in childhood [29].
Inclusion and Exclusion Criteria
The ideal population would enable independent assessment of
the contribution of SMN genotype, SMA type, present functional
status, and age in biomarker characterization. The age range
chosen excluded subjects less than 2 years of age – to avoid
metabolic confounders of infancy, nascent developmental accom-
plishments, and incomplete cooperation with the functional
outcome measure – and also excluded those over 12 years of
age to limit the contribution of puberty-related confounders [28].
Additional eligibility criteria highly restricted the use of potential
disease-modifying prescription medication and excluded children
who were affected by acute diseases, unrelated to SMA. SMA
subjects were required to have genetic confirmation of disabling
mutation of SMN1 and were defined into standard categories of
SMA by their history of ability (Type II) or inability (Type I) ever
to sit unaided for 30 seconds, or ability to ever stand and walk 30
feet unaided (Type III) [22]. To limit biased ascertainment of
individuals into the healthy control cohort that might shift the
proportion of single-copy SMN1 genomes from that of the normal
population, only those SMA siblings known by previous genetic
evaluation to have 2 or more copies of SMN1 were eligible. Initial
caps on the maximum number of subjects enrolled per site were
instituted to enhance broad applicability of results.
Statistical Analysis for SMN Copy Number, Transcript and
Protein
Potential predictors of SMN protein, transcript and copy
numbers included: age, gender, SMA diagnosis and type, and
current level of function as measured by the MHFMS.
Relationships among SMN protein, individual transcript types
(listed below), and copy numbers were examined as well. One
extreme outlier of SMN transcript ratios (SMN2-FL/SMN-D7
ratio, 26 standard deviations above the next highest value) was
removed from analysis of that outcome alone. Predictors of
continuous outcomes were assessed using analysis of covariance
(ANCOVA) for categorical predictors and partial correlation for
continuous predictors. As a significant effect of age was found for
some outcomes, all models were controlled for age. Data was log-
transformed to reduce the impact of skewed data. All analyses
were performed with SAS v9.2 (SAS Institute, Cary, NC), and
p,0.05 was considered statistically significant. By design, our
study cohort included subjects whose function fell outside the
range of MHFMS detection, and thus were scored the constrained
maximum or minimum MHFMS value. Because ceiling and floor
values will increase (positive) or decrease (negative) slopes of
identified associations we performed the statistical analysis of SMN
transcripts and protein to MHFMS comparisons by including and
excluding those with border values.
SMN Copy Number
Quantification of SMN1 and SMN2 copy number was
conducted at Expression Analysis Inc., Durham, North Carolina
by quantitative real-time Taqman PCR (qPCR) [30]. Genomic
DNA was isolated from whole blood samples using Gentra
Puregene Blood Kit (Qiagen). Externally validated DNA standards
for SMN1 and SMN2 were kindly provided by Dr. Wendy Chung
from Columbia University Medical Center, New York, NY. The
SMN1 and SMN2 reactions were carried out in 16TaqMan
Universal PCR master mix (Applied Biosystems) containing
300 nM of SMN1 primers, 250 nM of SMN probe or 450 nM
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Type II and III and
of SMN2 primers, 250 nM of SMN probe, 650 nM of SMN1
non-extending oligonucleotide, respectively. The non-extending
SMN1 oligonucleotide increases SMN2 assay specificity by
blocking nonspecific annealing of the allele-specific primer to the
opposite allele. To enable normalization of the input target DNA
added to each well, the internal control CFTR gene was amplified
simultaneously in a separate reaction well under identical thermal
cycling conditions. The CFTR reaction was carried out with
16TaqMan Universal PCR master mix containing 450 nM of
CFTR primers and 250 nM of CFTR probe. PCR was performed
on a 7900HT Sequence Detection System (Applied Biosystems)
using a 384-well format, and amplification was achieved using the
standard amplification protocol (Applied Biosystems) as follows:
50uC for 2 min, 95uC for 10 min, followed by 45 cycles of 95uC
for 15 s, and 60uC for 1 min. Each reaction was run in
quadruplicate with 25 ng of genomic DNA in a final volume of
15 ml. The number of SMN1 and SMN2 copies was calculated
using the comparative CT method [31]. Results were interpreted
separately by two independent investigators (Dr. Wendy Chung,
Columbia University Medical Center, NY, NY; and Dr. Louise
Simard, University of Manitoba, Winnipeg, Manitoba) and
confirmed in a separate analysis performed by Dr. Thomas Prior
at The Ohio State University using his published methodology
[27].
SMN Transcripts
Four specific transcripts were measured: (1) SMN2-Full Length
(SMN2-FL), (2) SMN1-Full Length (SMN1-FL), (3) SMN
transcript lacking exon 7 (SMN-D7), and (4) GAPDH, a
housekeeping gene commonly used for normalization in SMN
transcript analysis. Three combinations of these primary mea-
surements were also considered of potential relevance: (5) Total
SMN-FL (SMN1-FL+SMN2-FL), (6) Total SMN (SMN-
FL+SMN-D7), and (7) a ratio of SMN2 transcripts that reflects
exon 7 inclusion (SMN2-FL/SMN-D7). As SMN1-FL is only
found in control subjects, the values of SMN2-FL and Total SMN-
FL are the same in SMA subjects.
SMN2-FL and SMN1-FL levels in whole blood were evaluated
by absolute real-time PCR [26]. GAPDH transcript levels were
determined as positive controls both for reverse transcriptase PCR
(RT-PCR) and real-time PCR in similar fashion. Analysis of
SMN-D7 transcripts followed a procedure similar to that of
SMN1-FL and SMN2-FL transcript quantification using primers
SMN-D7-absF CTG ATG CTT TGG GAA GTA TGT TAA TT
and SMN-D7-absR CCA GCA TTT CCA TAT AAT AGC CAG
TA, and probe SMN-D7_absP 59FAM - CAT GGT ACA TGA
GTG GCT A -NFQ39.
SMN Protein
A total of 127 samples (SMA 105, control 22) were available for
SMN ELISA measurements. Whole blood was collected into
EDTA K2 tubes and approximately 4 mL was poured into CPT
vacutainers (#362760 BD, Franklin Lakes, NJ). PBMCs were
isolated by centrifugation at 1500 rpm within 2 hours of collection.
PBMC samples were shipped at ambient temperature to PPD for
further processing and frozen storage. Frozen samples were
transferred to Enzo Life Sciences (Ann Arbor, MI) for SMN
analysis. PBMCs were thawed in a 37uC water bath and viable cell
hemocytometer counts, performed immediately prior to lysis, were
used to determine the appropriate volume of lysis buffer (LB-11)
needed to establish a consistent concentration of the cell
suspension of 108 cells per milliliter. LB-11 containing 300 mM
NaCl, 10% glycerol, 3 mM EDTA, 1 mM MgCl2, 20 mM b-
glycerophosphate, 25 mM NaF and 1% Triton X-100 was used
along with protease inhibitors PIC8340 (Sigma #P8340, St. Louis,
MO) and phenylmethylsulphonyl fluoride (Sigma #P7626). The
cell suspension was gently vortexed and placed on ice for 30
minutes. The cell lysate was transferred to a 1.5 mL centrifuge
tube and was clarified by centrifugation for 10 minutes at 14,000
RCF, 4uC. The supernatant was transferred to a clean vial and
either assayed immediately or stored at –70uC until use.
Recombinant human SMN1 was generated from full-length
cDNA expressed in bacterial expression vectors and purified for
use as a standard in the ELISA. The capture antibody Sigma anti-
SMN clone 2B1 (#S2944) was coated at 100 uL onto Costar
Stripwell (#92592, Lowell, MA) at 3.5 ug/mL. After overnight
incubation at room temperature, the plate was blocked for 5 hours
with 1% BSA in PBS. Cell lysate samples and recombinant
hSMN1 or HeLa cell lysate standards were loaded at 100 uL per
well. Standards were diluted in 2-fold dilutions or from 0.0625-
4 ng/mL. Samples were incubated for one hour at room
temperature, washed and then incubated with a detection
antibody from ProteinTech (#11708-AP-1, Chicago, IL) at
2 ug/mL for one hour at room temperature. After washing, a
peroxidase conjugated goat anti-rabbit IgG from Jackson Im-
munolabs (5-#035-144, West Grove, PA) was applied at 50 ng/
mL to the plate and incubated for 30 minutes at room
temperature. After washing, plates were developed with TMB
substrate for 30 minutes at room temperature and the reaction
stopped after 30 minutes with 1N HCl acid. Plates were then read
on a spectrophotometer at 450 nm. Plates were sealed and gently
shaken during all incubations, and dilutions of sample and
standard were done in assay buffer (1% BSA, 0.1% Tween-20 in
PBS).
Results
Characteristics of the Study Cohort
A total of 130 subjects were enrolled, including 17 Type I, 49
Type II, 42 Type III SMA, and 22 healthy control subjects.
Enrollment figures slightly exceeded the original targets for each
group due to replacement, per protocol, of subjects in whom
specimens were of insufficient quantity (n = 7) or quality (n = 3). All
18 study sites contributed at least one subject over the course of 18
weeks concluding in March 2009. The age and gender distribution
of those enrolled is presented in the second table of companion
paper, Finkel et al [55]. Although age of onset correlates with
phenotype severity in SMA, a key recruitment goal of this study
was to minimize within the ascertained cohort the correlation
between present age and present functional status – because such
correlation might introduce an age bias into identified markers
and reduce the power of discrimination between factors associated
with SMN2 copy number, SMA type, and motor function. This
goal was achieved both overall and within SMA groups Type II
and III, and to a partial extent, SMA Type I (Figure 1, Table 1,
Figure S1 and Table S1, see companion paper, Finkel et al. [55]).
SMN2 Copy Number
Copy number of SMN2 varied in the SMA subjects from 1 to 6,
and distributed with SMA type in a manner consistent with
previous experience [1,2,32], confirming the hypothesis that there
is an inverse relationship between SMA severity and SMN2 copy
number in this cohort (Figure 2). SMN2 copy number increased
and was strongly associated (p= 0.002) with SMA type (Figure 2
and Table S2). SMA Types I and II most commonly had 2 and 3
copies of SMN2 respectively, and Type III SMA had 3 or 4 copies
of SMN2 (Table 2). This SMA cohort included a few prominent
outliers of the trend correlating SMA type to SMN2 copy number
SMN Expression in SMA
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including Type 1 subjects with high SMN2 copy number, and
Type III SMA subjects with a low SMN2 copy number.
Additionally, it was noteworthy that this cohort contained SMA
subjects with 5 or 6 copies of SMN2.
Deviations from the usual relationship between copy number
and SMA type further confirm that SMN2 copy number alone
does not predict individual phenotype severity. SMN2 copy
number was significantly lower in control subjects (p,0.001), with
values similar to other reports [1,33]. This trend, previously
reported, likely relates to two processes: (1) embryonic lethality of
genomes containing 0 copies of SMN1 and less than 2 copies of
SMN2, and (2) pathogenic SMA alleles often contain a conversion
type mutation wherein the sequence of SMN1 is converted to that
of SMN2, increasing SMN2 copy number in individuals with the
less severe forms of SMA [34–36].
Figure 3 shows the lack of a relationship between SMN2 copy
number and age, whether overall or by type, confirming the
success of the recruitment strategy to establish a cohort in which
SMA type and age were not correlated. In addition, there was no
correlation between SMN2 copy number and MHFMS score in
Type II or III SMA groups in isolation, or in the Type II+III
group combined, when subjects with maximum or minimum
MHFMS scores were removed (data not shown) (21 subjects with a
minimum score, and 42 subjects –22 with SMA and 20 control –
with a maximum score). There was no association between SMN2
copy number and gender. A post-hoc analysis determined that
exclusion of outlier subjects with high copy number did not result
in a meaningful change in any of the identified relationships.
SMN Transcripts, Age and Gender Comparisons
In a regression model controlling for SMA diagnosis and type,
SMN2-FL (p = 0.007), SMN-FL (p= 0.008) and SMN-total
(p = 0.036) transcript levels decrease with age. SMN-D7 and
GAPDH transcript levels did not change significantly with age
(Figure S1 and Table S1). There was no significant effect of gender
on any of the transcript measurements.
SMN Transcripts: Relationship to SMA Type, SMN Copy
Number, and MHFMS
The relationship of SMN transcripts to the three SMA types
and control groups is presented in Figure 4 and Table S2. SMN-
FL transcript levels increased with SMA type (Figure 4A, Table 2),
and levels in all three types were less than that found in controls,
Figure 1. Modified Hammersmith Functional Motor Scale
versus age by SMA cohort. Scores for the MHFMS were well-
distributed by age across the enrollment cohorts. It should be noted
that not all control individuals achieved a score of 40 on the scale, while
all Type I SMA subjects were assigned scores of zero in the assessment.
doi:10.1371/journal.pone.0033572.g001
Table 1. SMA and Control Subjects’ Clinical Data.
SMA Type I
N=17
SMA Type II
N=49
SMA Type III
N=42
Control
N =22
p-value*
Type I vs II vs III
p-value* SMA
vs Control
Age (years) 0.14 0.84
mean (SD) 5.70 (3.54) 6.55 (3.40) 7.51 (3.11) 6.95 (3.29)
median [range] 4.03 [2.39–12.66] 6.49 [2.16–12.98] 7.42[2.37–12.95] 6.02 [2.16–12.59]
Sex, n (%) 0.73 0.64
male 10 (58.8%) 26 (53.1%) 20 (47.6%) 10 (45.5%)
female 7 (41.2) 23 (46.9%) 22 (52.4%) 12 (54.6%)
MHFMS ,0.001 ,0.001
mean (SD) 0 (0) 14.02 (10.55) 34.1 (10.0) 39.8 (0.7)
median [range] 0 [0–0] 11 [0–36] 40 [2–40] 40 [37–40]
*ANOVA for continuous variables; Fisher exact test for categorical variables.
Legend: There were no significant differences in age or gender across the recruitment cohorts. The Modified Hammersmith Motor Function Scale differentiated
between SMA subjects and controls and between Type I, II and III subjects.
doi:10.1371/journal.pone.0033572.t001
Figure 2. SMN2 copy numbers in SMA and Control subjects.
SMN2 copy number is lower in Controls than it is in SMA subjects, in
whom copy number is related to type.
doi:10.1371/journal.pone.0033572.g002
SMN Expression in SMA
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due to the presence of SMN1. SMN2-FL transcript level increased
with SMA type (Figure 4A, Table 2), but it was similar for Type III
subjects and controls. As hypothesized, the analysis of subjects with
SMA revealed a significant difference for SMN2-FL (and hence,
Total SMN-FL) transcript levels for Type I vs Type II, Type I vs
Type III and Type II vs Type III (p = 0.031, ,0.001, 0.024,
respectively). SMN-D7 transcript level was higher in Type II and
III compared to Type I and controls (Figure 4B, Table 2). It is
notable that the ratio of SMN2-FL/SMN-D7 was similar within
SMA groups (Figure 4D, Table 2), and is higher in controls, which
was mostly driven by lower levels of SMN-D7 in controls.
Surprisingly, GAPDH transcript levels were significantly different
in SMA Type I versus Type II or III subjects (Figure 4E, Table 2).
A noteworthy finding is that within the SMA subject group
there was no association of SMN2-FL, (Total SMN-FL) or any
other transcript levels to SMN2 copy number. The only significant
association between any SMN transcript and SMN2 copy number
is that of SMN-D7 assessed in the whole study group combining
SMA and control subjects (r = 0.31, p = 0.003).
SMN2-FL and SMN-D7 transcript levels in SMA subjects
showed some modest relationships to MHFMS score when the
transcripts were assessed in all SMA subjects, including those with
a maximum or minimum MHFMS score value (r = 0.34, p = 0.009
for Type II+III only for SMN2-FL; r = 0.60, p = 0.0001 for Type
III only for SMN-D7). When the analysis was confined to the 67
subjects having non-maximum or minimum MHFMS scores – to
address the possible confounders associated with floor and ceiling
effects – the relationship between SMN2-FL and SMN-D7
transcripts and MHFMS was lost.
Table 2. SMA and Controls SMN Transcripts, Protein and Copy Number.
SMA Type I SMA Type II SMA Type III Control
SMN2 Copy Number N=16 N=48 N=42 N=21
mean (SD) 2.5 (0.9) 3.0 (0.7) 3.5 (0.8) 1.7 (1.1)
median [range] 2.1 [1.8–5.2] 2.9 [1.8–5.2] 3.2 [2.2–5.9] 1.3 [0.0–4.2]
SMN Protein (pg/106 cells) N=13 N=43 N=38 N=22
mean (SD) 10.1 (4.8) 14.0 (7.3) 14.7 (10.0) 25.2 (19.6)
median [range] 10.6 [2.3–19.4] 12.8 [1.6–33.1] 12.4 [3.1–45.8] 18.8 [5.0–86.2]
SMN2-FL Transcripts (mol/ng) N=13 N=36 N=31 N=13
mean (SD) 38.3 (16.3) 49.0 (18.6) 58.1 (20.0) 51.5 (22.3)
median [range] 32.1 [19.1–70.2] 48.9 [17.3–94.8] 54.2 [31.8–111.2] 55.6 [15.5–91.7]
SMN-FL Transcripts (mol/ng) N=13 N=36 N=31 N=13
mean (SD) 38.3 (16.3) 49.0 (18.6) 58.4 (19.7) 134.1 (65.1)
median [range] 32.1 [19.1–70.2] 48.9 [17.3–94.8] 54.2 [34.0–111.2] 129.9 [40.9–259.8]
SMN-D7 Transcripts (mol/ng) N=13 N=36 N=31 N=13
mean (SD) 140.6 (69.8) 202.6 (73.0) 200.4 (97.5) 115.2 (64.2)
median [range] 133.5 [65.5–320.8] 212.0 [54.4–316.9] 188.9 [52.8–400.0] 121.3 [16.2–236.9]
SMN-total Transcripts (mol/ng) N=13 N=36 N=31 N=13
mean (SD) 178.8 (76.5) 251.6 (82.1) 258.8 (110.5) 249.4 (98.3)
median [range] 163.1 [95.7–361.3] 278.2 [78.3–367.8] 247.4 [95.5–475.4] 267.6 [63.9–448.8]
SMN2-FL/SMN-D7 Transcripts N=13 N=36 N=31 N=13
mean (SD) 0.31 (0.13) 0.26 (0.09) 34.1 (0.16) 0.44 (0.15)
median [range] 0.33 [0.13–0.52] 0.27 [0.09–0.45] 0.28 [0.14–0.81] 0.42 [0.22–0.68]
GAPDH Transcripts (mol/ng) N=12 N=36 N=30 N=13
mean (SD) 4937.0 (1900.1) 3662.0 (1870.4) 3165.1 (757.5) 4251.5 (2079.1)
median [range] 4535.0 [2428.6–8180.0] 3298.5 [1450.0–7860.0] 3054.5 [1580.0–4520.0] 3570.0 [2230.0–9330.0]
Mean and median values of SMN transcripts, protein and copy number for SMA Type I, II, III and Controls. Transcript values are presented as number of molecules per ng
of total RNA (mol/ng).
doi:10.1371/journal.pone.0033572.t002
Figure 3. SMN2 copy number relationship to age, and by SMA
Type or Control. Subjects with each SMA type are broadly distributed
across the age range, with the exception of type I SMA for whom there
is some bias to younger age. As a consequence, SMN2 copy numbers
are also broadly distributed. Values have been plotted with a small y-
axis offset to avoid overlap of values.
doi:10.1371/journal.pone.0033572.g003
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SMN Protein
As expected, SMN protein was significantly lower in SMA
samples compared to control (Figure 5). Counter to our
expectations, SMN protein levels did not differentiate between
types (mean of 14.1, 14.0 and 14.7 pg/106 PBMCs for Types I, II
and III; Table 2). SMN protein levels did correlate with SMN2
copy number for all SMA subjects as one group (r = 0.33,
p = 0.001), with the largest contribution of that relationship from
Type II SMA subjects (r = 0.41, p = 0.008). SMN protein also
correlated with total SMN-FL transcript when all SMA subjects
are combined with controls (r = 0.26, p= 0.021). In addition, SMN
protein did not correlate with MHFMS.
Discussion
Blood-Derived Measures of SMN
This is the first report in which SMN2 copy number, and
transcript and protein measures of SMN expression in blood using
the quantitative assay methodologies that reflect the current
consensus in the field, have been applied prospectively to a large
and broad cohort of subjects with SMA. Tables 3 and 4
summarize qualitatively the many comparisons made in this study
between measurements of SMN copy number, SMN transcripts,
and SMN protein to the clinical variables of MHFMS, SMA type,
and SMA diagnosis to healthy controls; and the relationship of the
several SMN measures to one another.
Our findings confirm the data from previous blood sample
studies that show lower SMN-FL transcripts and protein in the
most severely affected subjects with SMA Type I [23–26]. In
addition, this study extends these findings to identify relationships
in milder types of SMA, confirming the findings of Tiziano et al.
Figure 4. SMN transcript concentrations in SMA and Control subjects. A,C: SMN2-FL, SMN-FL and Total SMN transcripts generally increase
with SMA Type. SMN-FL (A) is a sum of SMN1-FL (present only in healthy controls) and SMN2-FL. B: SMN-D7 expression levels are lower in Type I
patients compared to other SMA Types but they are similar to that of Controls. D: Ratios of SMN2-FL to SMN- D7 differ between SMA Types and
Controls, however differences between SMA Types are absent with the exception of Type II versus Type III patients. E: GAPDH transcript levels are
elevated in SMA Type I and Controls relative to Type II and III patients.
doi:10.1371/journal.pone.0033572.g004
Figure 5. SMN protein levels in SMA and Control Subjects.
While SMN protein levels are lower in SMA relative to Control subjects,
protein levels by SMA type are not statistically different from each
other.
doi:10.1371/journal.pone.0033572.g005
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[26] in a smaller cohort. GAPDH transcript levels were statistically
different between SMA Type I versus Type II and III patients,
suggesting a need for caution in the selection of housekeeping
genes for transcript normalization. This lends further support to
the use of methods based on absolute standard curves for
transcript analysis in order to avoid biases in data interpretation.
There was no relationship between any measure of SMN
expression and motor function as measured by the MHFMS
within the subset of subjects having non-maximum or non-
minimum scores. One important caveat to these findings is that
this functional scale was designed for children with SMA Type II.
In this study a MHFMS score was given to all subjects (SMA Type
I assigned a score of ‘‘0’’), but only subjects with SMA Type II and
those with Type III SMA who are no longer able to walk achieved
scores that were inside the minimum and maximum boundary
values of the scale. There is, at present, no validated instrument of
functional motor assessment that encompasses the entire range of
SMA into a single scale. Comparisons of blood derived measures
of SMN expression to subject motor function were thus necessarily
constrained to a subgroup of subjects. Previous findings [26] of an
association of SMN transcript levels to MHFMS may be due to
small sample size of the cohort, to the inclusion of maximum and
minimum MHFMS value patients, and stronger correlations
between SMA type, age, and MHFMS within that cohort
compared to this study selectively recruited to minimize these
confounders. It is possible that significant associations of blood
measures of SMN expression might be possible for other
assessments of motor function that target the ranges above or
below that assessed by the MHFMS. One consideration for future
work is to extend the analysis made here for MHFMS to
additional functional tests that better evaluate patients with higher
and lower function, as well as do a longitudinal assessment of SMA
patients across functional groups.
SMN2 copy number is grossly related to the disease severity but
has only modest predictive value for individual patients. SMN
transcript levels were reduced in patients compared to controls in a
manner graded by SMA type. The differences in SMN-FL
abundance relative to SMA type (Figure 4) are modest when
compared to the more substantial differences in SMN-FL
comparing SMA as a group to healthy controls. This finding
supports a hypothesis derived from the genetic epidemiology of
SMA, that the differences in SMN expression capacity between
SMA types are relatively small. Embryos inheriting only a single
copy of SMN2 are subject to early lethality. The differences in
clinical expression between those with 2 and 3 copies SMN ranges
from early death to easy ambulation, indicating a substantial role
of small differences in SMN production capacity. These small
differences are apparent in the small group differences found in
SMN-FL concentration between SMA Types I, II, and III. Given
the wide overlap for SMN transcript levels among the different
SMA types, these measures may not have prognostic value as
stand-alone measures. Determination of their ultimate predictive
value thus requires further exploration, and in particular re-
examination in the context of treatment with SMN-targeting
drugs.
A notable finding is that SMN2-FL (Total SMN-FL) transcript
abundance correlates with SMA type, but not with SMN2 copy
number, but SMA type and SMN2 copy number are themselves
highly correlated. A similar lack of correlation between SMN
transcript and SMN2 copy number was found previously [26],
though the smaller cohort size in that study limited the impact of
the observation. The fact that SMN transcript is more powerfully
associated with SMA type than with SMN2 copy number could
identify a molecular basis for the lack of a tight prediction of SMA
type by SMN2 copy number. The absence of correlation between
SMN2 copy number and SMN2-FL transcript level may be the
consequence of (1) differences in regulation of transcription and
alternative splicing of individual SMN2 genes, (2) the presence of
non-intact variants of the gene, (3) variability in stability of SMN2
transcripts, (4) differences at the genomic level among SMN2
genes [37], (5) high variance in SMN levels or any combination of
these factors. These factors might also contribute to additional
variability in SMN2-FL levels among SMA patients.
The lack of strong correlation between SMN protein levels, and
SMN2 copy number or transcript levels in SMA patients suggests
that there may be significant modulation of SMN at the
posttranscriptional level. This regulation could be different for
different cell types and tissues and it may also vary by age.
Moreover, it should be pointed out that PBMCs may not fully
reflect SMN expression levels in more disease relevant cells like
motor neurons, muscle, or both. There is a large body of evidence
that suggests that other genetic modifiers of SMN can significantly
impact SMA phenotype in animal models and humans [38–41]. In
addition, the inclusion or exclusion of exon 7 into SMN2
transcripts is controlled by several protein factors that could
contribute to the levels of full-length transcripts [42–54]. It is
similarly understood that the functional outcome measures
assessed in this study are also subject to a wide range of factors.
Nevertheless, these results confirm that SMN transcript and
protein are measureable in blood, that there is important inter-
patient variability in transcript and protein levels, and that neither
transcript, protein nor SMN2 copy number are solely predictive of
phenotype. It will be critical to explore changes in intra-patient
transcript and protein levels over time and in other tissues and the
regulatory factors governing transcription and translation.
Table 3. Summary of SMN associations: Pairwise analysis
between various SMA groups.
SMA group vs. control Between SMA types
SMN2 copy number Yes Yes
SMN2-FL transcript No Yes
SMN protein Yes No
The ‘‘Between SMA types’’ column includes the following comparisons: Type I
vs Types II+III, Type I vs Type II, Type I vs Type III, Type II vs Type III.
doi:10.1371/journal.pone.0033572.t003
Table 4. Associations between SMN2 copy number, SMN2
full-length transcript, SMN protein and MHFMS.
SMN2
copynumber
SMN2-
FLtranscript MHFMS
SMN2 copy number N/A No No
SMN2-FL transcript No N/A No
SMN protein Yes* No No
The ‘‘SMN2 copy number’’ and ‘‘SMN-FL transcript’’ columns include the partial
correlation analysis for SMA+Controls, SMA (all SMA patients), Type I, Type II,
Type III, Controls. The ‘‘MHFMS’’ column includes the analysis for Type II, Type III
and Type II+Type III with exclusion from the analysis of subjects having
minimum or maximum scores.
*Correlation was only found for the SMA group (r = 0.33, p = 0.001) and Type II
group (r = 0.41, p = 0.008).
doi:10.1371/journal.pone.0033572.t004
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The absence of an association of SMN transcripts or protein to
motor function as assessed by MHFMS might be expected, as
SMA likely progresses due to downstream cellular consequences of
diminished SMN abundance. This is a robust negative finding, as
the power of this study cohort was aided by the successful
recruitment of a wide and evenly distributed range of SMA type,
SMN genotype, motor function and age. Nevertheless, these
findings do not preclude further exploring measures of SMN
expression in blood as a biomarker of early pharmacodynamic
assessment of in vivo ‘‘target engagement’’ of a putative SMN-
enhancing agent.
Further studies are also needed to evaluate the potential value of
blood-derived measures of SMN expression to SMA therapeutics.
The first will be to understand better its performance as a clinical
measure. An important extension of this initial cross-sectional
analysis will be a longitudinal analysis of individual patients, across
the spectrum of SMA type and age, to evaluate the stability of
measures of SMN expression over time. The extent to which
measures of SMN transcript or protein values in blood are stable
in repeated within-subject measurements, as suggested by
preliminary findings [26] will determine the power of these assays
to evaluate a systemically delivered SMN-enhancing therapeutic
agent. A second line of investigation will be to assess the
relationship of blood-derived measures of SMN to that of other
tissues, and in particular to the expression of SMN in the CNS. To
some extent this can be done by comparing SMN transcript and
protein in the more difficult, but still accessible, tissues such as skin
and muscle, or from CNS tissues available from post-mortem
samples of subjects with SMA. Alternatively, comparing blood to
CNS-derived measures of SMN expression in relevant animal
models may be useful to establish the strength of any relationship
between the two. Other future studies that may be valuable to
clinical trials, and a better understanding of the biology of SMA
and SMN-depletion, would be to identify of the relationship of
candidate biomarkers found in the companion study to the
markers of SMN abundance identified here.
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